Structures by: Trostianko P. V.
Total: 17
3-(5-Phenyl-1,3,4-oxadiazol-2-yl)-2<i>H</i>-chromen-2-one
C17H10N2O3
Acta Crystallographica Section C (2019) 75, 11
a=15.611(5)Å b=3.8414(9)Å c=21.974(7)Å
α=90° β=90.74(3)° γ=90°
3-(5-Phenyl-1,3,4-oxadiazol-2-yl)-2<i>H</i>-chromen-2-one
C17H10N2O3
Acta Crystallographica Section C (2019) 75, 11
a=3.9158(8)Å b=17.717(3)Å c=18.832(3)Å
α=90° β=94.670(16)° γ=90°
3-[5-(Pyridin-4-yl)-1,3,4-oxadiazol-2-yl]-2<i>H</i>-chromen-2-one
C16H9N3O3
Acta Crystallographica Section C (2019) 75, 11
a=20.931(2)Å b=3.7708(5)Å c=16.0887(15)Å
α=90° β=90° γ=90°
3-[5-(Pyridin-4-yl)-1,3,4-oxadiazol-2-yl]-2<i>H</i>-chromen-2-one
C16H9N3O3
Acta Crystallographica Section C (2019) 75, 11
a=3.7788(9)Å b=9.9655(17)Å c=16.899(3)Å
α=90° β=93.466(19)° γ=90°
3-(3-Phenyl-1<i>H</i>-1,2,4-triazol-5-yl)-2<i>H</i>-1-benzopyran-2-one
C17H11N3O2
Acta Crystallographica Section C (2019) 75, 6 822-832
a=6.8415(7)Å b=10.8931(12)Å c=20.163(2)Å
α=74.965(9)° β=83.815(9)° γ=72.183(10)°
3-(3-Phenyl-1<i>H</i>-1,2,4-triazol-5-yl)-2<i>H</i>-1-benzopyran-2-one
C17H11N3O2
Acta Crystallographica Section C (2019) 75, 6 822-832
a=6.8355(11)Å b=19.512(3)Å c=10.881(2)Å
α=90° β=107.811(19)° γ=90°
3-(3-Phenyl-1<i>H</i>-1,2,4-triazol-5-yl)-2<i>H</i>-1-benzopyran-2-one
C17H11N3O2
Acta Crystallographica Section C (2019) 75, 6 822-832
a=13.0369(8)Å b=13.0804(7)Å c=16.2223(8)Å
α=90° β=90° γ=90°
C17H14N2O2
C17H14N2O2
Acta Crystallographica Section B (2019) 75, 5
a=4.8956(7)Å b=9.6425(15)Å c=14.958(2)Å
α=103.662(13)° β=94.580(12)° γ=98.382(12)°
C16H12N2O2
C16H12N2O2
Acta Crystallographica Section B (2019) 75, 5
a=4.8281(10)Å b=8.5805(13)Å c=15.436(2)Å
α=96.790(13)° β=95.002(15)° γ=91.404(15)°
C16H11FN2O2
C16H11FN2O2
Acta Crystallographica Section B (2019) 75, 5
a=4.6371(13)Å b=8.957(3)Å c=15.788(6)Å
α=99.88(3)° β=96.61(3)° γ=93.21(3)°
C16H11FN2O2
C16H11FN2O2
Acta Crystallographica Section B (2019) 75, 5
a=4.6995(14)Å b=30.579(8)Å c=8.853(3)Å
α=90° β=92.70(2)° γ=90°
C16H11ClN2O2
C16H11ClN2O2
Acta Crystallographica Section B (2019) 75, 5
a=4.3746(9)Å b=30.823(5)Å c=9.855(3)Å
α=90° β=93.225(17)° γ=90°
C16H11BrN2O2
C16H11BrN2O2
Acta Crystallographica Section B (2019) 75, 5
a=4.1661(2)Å b=31.0277(16)Å c=10.4434(6)Å
α=90° β=92.933(4)° γ=90°
C16H11BrN2O2
C16H11BrN2O2
Acta Crystallographica Section B (2019) 75, 5
a=6.9397(5)Å b=10.2611(8)Å c=20.7644(12)Å
α=90° β=96.919(7)° γ=90°
C16H11IN2O2
C16H11IN2O2
Acta Crystallographica Section B (2019) 75, 5
a=6.9395(2)Å b=10.2583(4)Å c=20.7605(6)Å
α=90° β=96.931(3)° γ=90°
C17H14N2O3
C17H14N2O3
Acta Crystallographica Section B (2019) 75, 5
a=6.9921(13)Å b=10.1424(15)Å c=20.862(3)Å
α=90° β=99.570(16)° γ=90°
3-(5-Phenyl-1,3,4-oxadiazol-2-yl)-2<i>H</i>-chromen-2-one
C17H10N2O3
Acta Crystallographica Section C (2019) 75, 11
a=13.9075(11)Å b=5.1543(5)Å c=18.8010(16)Å
α=90° β=97.772(8)° γ=90°